LMC Diabetes & Endocrinology Ltd.
22
3
3
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.5%
1 terminated/withdrawn out of 22 trials
92.3%
+5.8% vs industry average
27%
6 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Role: collaborator
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Role: lead
REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education
Role: lead
Real-world Effect of Switching From Intermittently-scanned to Real-time Continuous Glucose Monitoring (Switch CGM Retro)
Role: lead
Effect of Switching From Intermittently Scanned to Real-time Continuous Glucose Monitoring on Diabetes Management in Adults With Type 2 Diabetes (Switch CGM T2D)
Role: lead
Real-world Effects of Using Intermittently Scanned Continuous Glucose Monitoring and Pharmacist-led Coaching on the Management of Type 2 Diabetes Among Adults Not Using Insulin (REAL isCGM T2D)
Role: lead
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
Role: lead
Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)
Role: lead
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
Role: lead
The Canadian Diabetes Prevention Program
Role: lead
Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population
Role: lead
The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
Role: lead
Real-world Health Outcomes in Canadian Patients Using Semaglutide
Role: lead
Canadian Real-World Outcomes of Omnipod Initiation in People With T1D
Role: lead
The Current Health Status of Patients Living With Type 1 Diabetes From the LMC Diabetes Patient Registry
Role: lead
Randomized Trial Comparing Colesevelam vs. Ezetimibe
Role: lead
Approaches To Therapy Escalation In T2D
Role: lead
The Skills, Confidence & Preparedness Index (SCPI)
Role: lead
Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered
Role: lead
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
Role: lead